Es­pe­ri­on stock halved af­ter Dai­ichi dis­cord over $440M heart pill mile­stones

Es­pe­ri­on’s CLEAR Out­comes tri­al does not have a clear out­come re­gard­ing part­ner Dai­ichi Sankyo pony­ing up the big biobucks.

Es­pe­ri­on’s heart pill, which has strug­gled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER